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Abstract
Background: Salmonella enterica serotype Typhi is a human-restricted intracellular pathogen and the cause of typhoid fever.
Cellular immune responses are required to control and clear Salmonella infection. Despite this, there are limited data on
cellular immune responses in humans infected with wild type S. Typhi.
Methodology/Principal Findings: For this work, we used an automated approach to purify a subset of S. Typhi proteins
identified in previous antibody-based immuno-affinity screens and antigens known to be expressed in vivo, including StaF-
putative fimbrial protein-STY0202, StbB-fimbrial chaperone-STY0372, CsgF-involved in curli production-STY1177, CsgD-
putative regulatory protein-STY1179, OppA-periplasmic oligopeptide binding protein precursor-STY1304, PagC-outer
membrane invasion protein-STY1878, and conserved hypothetical protein-STY2195; we also generated and analyzed a
crude membrane preparation of S. Typhi (MP). In comparison to samples collected from uninfected Bangladeshi and North
American participants, we detected significant interferon-c responses in PBMCs stimulated with MP, StaF, StbB, CsgF, CsgD,
OppA, STY2195, and PagC in patients bacteremic with S. Typhi in Bangladesh. The majority of interferon-c expressing T cells
were CD4 cells, although CD8 responses also occurred. We also assessed cellular proliferation responses in bacteremic
patients, and confirmed increased responses in infected individuals to MP, StaF, STY2195, and PagC in convalescent
compared to acute phase samples and compared to controls. StaF is a fimbrial protein homologous to E. coli YadK, and
contains a Pfam motif thought to be involved in cellular adhesion. PagC is expressed in vivo under the control of the
virulence-associated PhoP-regulon required for intra-macrophage survival of Salmonella. STY2195 is a conserved
hypothetical protein of unknown function.
Conclusion/Significance: This is the first analysis of cellular immune responses to purified S. Typhi antigens in patients with
typhoid fever. These results indicate that patients generate significant CD4 and CD8 interferon-c responses to specific S.
Typhi antigens during typhoid fever, and that these responses are elevated at the time of clinical presentation. These
observations suggest that an interferon-c based detection system could be used to diagnose individuals with typhoid fever
during the acute stage of illness.
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Salmonella enterica serotype Typhi is a human-restricted intracel-
lular pathogen and the cause of typhoid fever. It is estimated that
over 20 million cases of S. Typhi infection occur each year,
resulting in approximately 200,000 deaths per year globally [1].
Current typhoid vaccines provide 50–75% protection for 2–5
years [2]. Mediators of protective immunity against typhoid are
incompletely understood. S. Typhi is an invasive enteropathogen
that, following ingestion, transits through intestinal epithelial cells,
is taken up by professional phagocytic cells, survives within
macrophages, and systemically circulates [3,4,5,6]. Antibody
responses to lipopolysaccharide (LPS), flagellin, Vi capsular
polysaccharide, and crude whole cell preparations have been
documented, and antibody responses are the basis of the Widal
serologic diagnostic assay for typhoid fever [7,8,9,10,11]. Howev-
er, with the exception of antibody responses against the S. Typhi
capsule (Vi antigen) [12], antibody responses may play a limited
role in mediating protective immunity during typhoid fever.
S. Typhi is an intracellular pathogen, and cellular immune
responses are required to control and clear S. Typhi infections
[10,13,14,15]. Unfortunately, there are limited data on antigen-
specific cellular responses during human wild type S. Typhi
infection. What is known is largely derived from analyses of
cellular responses in mice infected with S. Typhimurium
[16,17,18]; however, S. Typhimurium does not cause a typhoidal
illness in humans, and S. Typhi and S. Typhimurium differ
significantly at the genomic level [17,19,20]. Direct analysis of
cellular responses during S. Typhi infection in humans either pre-
dates modern immunologic techniques [21] or involves charac-
terizing immune responses in recipients of live attenuated oral
typhoid vaccines [22,23]. These analyses have shown that CD4
+
and CD8
+ T cells are critical to the development of protective
immunity to Salmonella, and control of Salmonella infection involves
prominent expression of interferon-c by both CD4 and CD8 cells
[24,25,26]. To date, however, there is less information on the
cellular responses in humans during wild type infection, especially
to purified S. Typhi antigens.
To address this, we used a modification of an automated
approach to purify a subset of S. Typhi proteins for use in
immunologic assays [27]. We selected antigens for evaluation
based on our previous application of a high throughput immuno-
affinity screen, In Vivo Induced Antigen Technology (IVIAT), to
S. Typhi [28]. Here we describe purification of a subset of these
proteins, and evaluation of interferon-c and cellular proliferation
responses to these antigens in humans with S. Typhi bacteremia in
Bangladesh. We also assessed responses to a crude membrane
preparation of S. Typhi.
Materials and Methods
Generation of expression clones for antigen production
We selected 58 S. Typhi proteins contained within operons
identified during our previous application of IVIAT to S. Typhi
[28]. IVIAT identifies proteins expressed in vivo during human
infection and that generate an antibody response [28]. We
obtained pDONR221 Gateway Based entry clones of the S. Typhi
CT18 genes corresponding to selected proteins from the NIAID-
sponsored Pathogen Functional Genomic Resource Center, J.
Craig Venter Institute (JCVI, formerly The Institute for Genomic
Research). We used LR clonase II enzyme reactions (Invitrogen,
Carlsbad, CA) as per the manufacturer’s instructions to move
inserts into pDEST17 (Invitrogen, Carlsbad, CA) to generate a
fusion containing an amino terminal 66 histidine (HIS) tag. We
transformed DH5alpha-T1R competent cells with LR reactions
and selected for ampicillin resistance. We confirmed insert
presence by restriction digestion and PCR analysis and trans-
formed purified plasmids into E. coli protein expression strain
BL21 star (DE3) pLysS (Invitrogen).
Protein expression
We grew transformants harboring recombinant plasmids at
37uC as 1.5 ml cultures in 96-well blocks (Marsh Biomedical
Products) to an OD600 of 0.6–0.8. We induced cultures with 1 mM
isopropyl b-D-1-thiogalactopyranoside (IPTG) on a 96-well plate
shaker (Multitron) (6900 rpm). After 3 hours at 37uC, we
harvested cells at 4uC and stored preparations at 280uC for
further use. We also induced BL21 star (DE3) pLysS containing
pDEST17 but lacking an S. Typhi insert. This construct produced
a truncated HIS-tagged protein MSYYHHHHHHLESTSLYK-
KAERERKMI that we recovered and used as a control protein in
immunological assays.
Automated 96-well protein purification
We performed protein purifications in 96-well plates using a
BiomekFx (Beckman Coulter) robotic liquid handler as previously
described [27]. For this 6xHIS denaturing affinity purification, we
thawed cell pellets at room temperature for 15 min, lysed them in
the presence of protease inhibitors in 115 ml lysis buffer I (100 mM
NaH2PO4, 10 mM Tris, pH 8.0), robotically resuspended product
in a 96-well block and agitated at 900 rpm for 10 min (5 min in
the clockwise direction and 5 min in the counterclockwise
direction). We then added 10 ml of DNase mix (10 mg/ml DNase;
Sigma Aldrich in 900 mM MgCl2, 100 mM MnCl2) to the lysate
and agitated the preparation at 900 rpm for 10 min. Next, we
added 115 ml of lysis buffer II (100 mM NaH2PO4, 10 mM Tris,
6 M guanidine hydrochloride, 10 mM, 2-mercaptoethanol,
pH 8.0) to create denaturing conditions. We then allowed these
cell lysates to bind to 30 ml of MagneHIS beads (Promega) with
shaking at 900 rpm for 20 min (10 min clockwise, 10 min
counterclockwise), and separated beads using a magnabot (24-
pin magnet; Promega). The robotic liquid handler then washed
the MagneHIS beads with bound protein three times with wash
buffer (100 mM NaH2PO4, 10 mM Tris, 8 M urea). We
prevented bead adherence to the walls during washing by shaking
the samples at 900 rpm for 2.5 min clockwise and then 2.5 min
Author Summary
Salmonella enterica serotype Typhi infection is a significant
global public health problem and the cause of typhoid
fever. Salmonella are intracellular pathogens, and cellular
immune responses are required to control and clear
Salmonella infections. Despite this, there are limited data
on cellular immune responses during wild type S. Typhi
infection in humans. Here we report the assessment of
cellular immune responses in humans with S. Typhi
bacteremia through a screening approach that permitted
us to evaluate interferon-c and proliferation responses to a
number of S. Typhi antigens. We detected significant
interferon-c CD4 and CD8 responses, as well as prolifer-
ative responses, to a number of recombinantly purified S.
Typhi proteins as well as membrane preparation in
infected patients. Antigen-specific interferon-c responses
were present at the time of clinical presentation in patients
and absent in healthy controls. These observations could
assist in the development of interferon-c-based diagnostic
assays for typhoid fever.
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using 100 ml of distilled water, and added 50 ml distilled water to
make the final suspensions for analysis. We repeated this
extraction cycle six times.
Automated 96-well protein analysis
We analyzed proteins in a 96-well format using a capillary-
based instrument, the LabChip90 (Caliper Sciences). We
automated a system that resuspended 3 ml of protein sample in
7 ml analysis buffer (Caliper Sciences), heated these to 96uCf o r
5 min., cooled them to room temperature, and briefly centri-
fuged to collect the sample. We added distilled water (35 ml) to
each sample prior to analysis. We primed the analysis chip
(Caliper Sciences) according to the manufacturer’s instructions.
The automated protein analysis generated three different forms
of output: a chromatogram that showed migration time; a virtual
gel that mimicked a Coomassie stained gel; and a results table
that included the estimated size, quality, and quantity of each
peak. The LabChip90 analyzed 96 proteins at a time with
analysis time of 40 seconds per sample. We parsed the output
results and imported them into the Harvard Institute of
Proteomics protein database. We assessed for presence of
contaminating E. coli LPS using a HEK-Blue LPS Detection kit
(InvivoGen, San Diego, CA).
Production and mass spectrometric analysis of S. Typhi
crude membrane preparation
We prepared S. Typhi membrane preparation as previously
described [29,30]. Briefly, we cultured S. Typhi Ty21a on sheep
blood agar plates and harvested in Tris buffer (10 mM Tris,
pH 8.0, 5 mM MgCl2). We sonicated the mixture, and centrifuged
at 14006g for 10 minutes and transferred the supernatant to fresh
tubes, centrifuging at 149006g for 30 minutes. We suspended the
pellet in 10 ml Tris buffer, and determined the protein content by
the BioRad Protein Assay per the manufacturer’s instructions.
We performed mass spectrometric analysis of the S. Typhi
membrane preparation as previously described using a LTQ-
Orbitrap XL (Thermo Fisher Scientific) instrument [19,31]. We
identified peptides using SEQUEST (Thermo Fisher Scientific)
through Bioworks Browser, version 3.3.1 SR1. MS/MS data were
obtained using 10 ppm mass accuracy on precursor m/z and a 0.5
Da window on fragment ions. Fully enzymatic tryptic searches
with up to three missed cleavage sites were allowed. Oxidized
methionines were searched as a variable modification and
alkylated cysteines were searched as a fixed modification.
Salmonella databases for CT18 were downloaded from EMBL-
EBI and supplemented with common contaminants. We employed
a reverse database strategy [32] using concatenating reversed
protein sequences for each database entry in SEQUEST. We
filtered peptides for each charge state to a false discovery rate
(FDR) of 1%, and then grouped peptides into proteins using
Occam’s razor logic. A full listing of proteins identified in mass
spectrometric analysis of Salmonella Typhi membrane preparation
is available in the supplemental material (Table S1).
Collection of specimens from study subjects
Individuals (1–59 years of age) with fever of 3–7 days duration
($39uC) having clinical symptoms and signs suggestive of typhoid
fever and lacking an alternate diagnosis who presented to the
Kamalapur field site of the International Centre for Diarrhoeal
Disease Research, Bangladesh (ICDDR,B) Dhaka hospital were
eligible for enrollment. We collected venous blood (for children
,5 years of age, 3 ml of blood; for older individuals, 5 ml of
blood) for culture (n=69). We used the BacT/Alert automated
system and identified S. Typhi organisms using standard
biochemical methods and by reaction with Salmonella-specific
antisera [30,33]. Following informed consent from patients or
guardians in the case of children, we collected an additional 5 ml
of blood from bacteremic individuals within 72 hours of the
patient presenting for medical care, and a follow-up sample 21–
28 days later (n=16; ages 2–22 years). All patients with 3 days or
longer of fever were treated initially with amoxicillin or cefixime
at the discretion of the attending physician until scheduled follow-
up 48–72 hours later, or sooner as clinically indicated. Individ-
uals with documented S. Typhi bacteremia were continued on
amoxicillin if they showed signs of improvement and their blood
isolates showed sensitivity to first line treatment; or were switched
to parenteral ceftriaxone or oral ciprofloxacin, if their isolates
were not sensitive and/or they failed to improve by 72 hours;
therapy was continued for up to 14 days, or up to 7 days beyond
defervescence, whichever occurred first. All patients recovered.
We also collected 5 ml of blood from North American volunteers
(n=3) without a history of international travel who had never
received typhoid vaccination and who did not have previous
known Salmonella infection, and we collected 5 ml of blood from
healthy Bangladeshi volunteers (n=4) who did not have illness,
fever or diarrhea in the preceding three months [34]. Studies
were approved by the Institutional Review Boards of the
ICDDR,B and Massachusetts General Hospital.
PBMC isolation
We diluted heparinized blood in phosphate buffered saline
(PBS; 10 mM, pH 7.2) and isolated peripheral blood mononuclear
cell (PBMC) by gradient centrifugation on Ficoll-Isopaque
(Pharmacia, Uppsala, Sweden). We re-suspended isolated PBMCs
to a concentration of 1610
6 cells/ml in RPMI complete medium
RPMI-1640 (Gibco, Gaithersburg, Md) with 10% heat-inactivated
fetal bovine serum (Hyclone-Thermo Scientific, Waltham, MA,
USA), 100 units/ml penicillin, 100 mg/ml streptomycin, 100 mM
pyruvate, and 200 mM L-glutamine (Gibco) [35].
Interferon gamma ELISPOT assay
We used PBMCs to measure human interferon-c expression
using an ELISPOT format with MabTech antibodies, according
to the manufacturers’ instructions (Mabtech Inc, Cincinati, OH,
USA). In brief, we coated 96-well nitrocellulose plates (Multiscreen
HTS, Millipore) with 100 mlo f1 5mg/ml human monoclonal anti-
interferon-c antibody (1-D1K) overnight at 4 ˚C. Following washing
the plates and subsequent blocking with 10% FBS for 2 h at room
temperature, we added PBMCs from individual patients or
controls at a concentration of 2610
5 per well for each
experimental condition. We added individual S. Typhi antigens
or control protein to wells at a concentration of 140 ng/well of
total preparation for each purified antigen (in 200 ml culture, final
concentration 0.7 mg/ml). In separate wells, we also added S.
Typhi membrane preparation at a final concentration of 10 mg/ml
in 200 ml culture, phytohaemagglutinin (PHA; Murex Diagnostics
Ltd, Temple Hill, UK) at a final concentration of 2.5 mg/ml in
200 ml culture, and keyhole limpet hemocyanin (KLH). We
included additional control wells with media but lacking antigen.
Following incubation of plates at 37uCi n5 %C O 2 for 20 hours,
we washed plates, added biotinylated monoclonal anti-interferon-c
antibody (7-B6-1-biotin; 1:500 dilution), incubated plates at room
temperature for an additional 2 hours, washed them, added
streptavidin-HRP (1:500 dilution), and re-incubated for 1 hour at
room temperature. We developed plates with aminoethylcarbazol
plus H2O2, and counted interferon-c secreting cells using a
Interferon-c and Cellular Responses during Typhoid
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media only and expressed results as the number of spots/10
6
PBMC in each experimental condition [36].
Intracellular cytokine staining
To characterize the interferon-gamma T cell response further,
we resuspended PBMCs at a concentration of 1610
6 cells/mL in
RPMI medium (Gibco, Carlsbad, CA) and supplemented with
10% fetal calf serum (FCS, Gibco). We cultured PBMCs in U-
bottom tissue culture plates (Nunc, Denmark) in the presence of
Salmonella membrane preparation (MP; 10 mg/ml), StaF (7 mg/
ml), PagC (7 mg/ml), KLH (2.5 mg/ml as a negative control) or
PMA (5.0 ng/ml as a positive control; Phorbol 12-myristate 13-
acetate) with ionomycin (1.0 mg/ml). Samples containing only
unstimulated cells were included to assess in vivo stimulation. We
used 1.0 mg/ml of anti-CD28 (clone 28.2; BD Pharmingen) and
anti-CD49d (clone 9F10; BD Pharmingen) for co-stimulation. We
incubated PBMCs and antigens for 2 hours at 37u Ci n5 %C O 2.
After 2 hours, we added 10 mg/mL of brefeldin A (BFA, Sigma)
and continued incubating the plates for an additional 4 hours
[37]. Following stimulation, we washed cells with PBS and 2%
FCS. We then stained cells for 30 min at 4uC with the following
surface monoclonal antibodies: anti-CD3-APC, anti-CD4–
perCP, and anti-CD8-FITC (Becton Dickinson, San Jose,
USA). Following surface staining, we washed the cells and
incubated the preparations with FACS Lysing Solution (BD
Bioscience) for 10 minutes, and then re-washed and permeabi-
lized the preparations with FACS permeabilizing solution (BD
Bioscience) for 10 min at room temperature. We washed the
permeabilized cells and stained them for 30 min at 4uCw i t h
fluorochrome-conjugated anti-IFN-c-PE (BD Bioscience). Fol-
lowing staining, we re-washed the cells, and fixed them in
formaldehyde before performing flow cytometry using a FACS
Calibur (BD, San Jose, CA) [37]. We identified the lymphocyte
population on forward versus side scatter plot, then gated
CD3
+CD4
+ and CD3
+CD8
+ subpopulations, and identified
CD4
+IFN-c
+ and CD8
+IFN-c
+ subpopulations. We subtracted
unstimulated responses, and expressed results as interferon-c
+ T
cells per 1066P B M C .
T-cell proliferation assay
To evaluate proliferative responses to antigens, we cultured
PBMCs (10
5 cell per well) in DMEM/F12 medium (Gibco,
GlutaMAX) supplemented with 1% gentamicin and 5% human
AB+ serum in triplicate wells in round-bottomed 96-well plates.
We added S. Typhi antigens and controls to wells at the same
concentrations used in the interferon-c ELISPOT assay and with a
final culture volume of 200 ml. We incubated plates at 37uCi n5 %
CO2 for 5 days. After 48 h incubation, we replaced 100 ml of the
medium per well with fresh medium. After 5 days of incubation,
we added
3H-thymidine (1 mCi) to each well under sterile
conditions, incubated plates for an additional 8 hours, harvested
cells in Bray’s scintillation fluid (Ultimagold, PerkinElmer, Boston,
MA) using a cell harvester (Skatron instruments, Norway), and
assessed [
3H] thymidine incorporation using a liquid scintillation
b-counter (Beckman LS6500 multipurpose scintillation counter,
USA) as previously described [22,38]. We expressed results as
counts per minute (cpm), and calculated stimulation indices for
each antigen according to the formula: net cpm with antigen /net
cpm without antigen (media alone) for each individual on each day
(day 5 and day 20) [39].
Table 1. S. Typhi protein preparations used in this study.
STY number Annotated name Protein
STY0202 Putative fimbrial protein StaF
STY0372 Fimbrial chaperone protein StbB
STY1177 Assembly/transport component in curli production CsgF
STY1179 Putative regulatory protein CsgD
STY1304 Periplasmic oligopeptide-binding protein precursor OppA
STY1878 Outer membrane invasion protein PagC
STY2195 Conserved hypothetical protein
Membrane preparation Crude membrane preparation containing at least 934 S. Typhi proteins (see Tables 2 and 3) MP
doi:10.1371/journal.pntd.0001193.t001
Table 2. Functional categories of proteins detected in S.
Typhi membrane preparation.
Classification Number of proteins
Energy metabolism 134
Unknown function or unclassified 105
Cell envelope 90
Hypothetical proteins 83
Protein synthesis 77
Transport and binding proteins 74
Protein fate 65
Pathogenesis/virulence/cellular processes 59
Central intermediary metabolism 42
Regulatory functions 39
DNA metabolism 38
Amino acid biosynthesis 30
Biosynthesis of cofactors, prosthetic groups, and
carriers
28
Purines, pyrimidines, nucleosides, and nucleotides 25
Transcription 19
Fatty acid and phospholipid metabolism 18
Mobile and extrachromosomal element functions 4
Viral functions 4
Total 934
doi:10.1371/journal.pntd.0001193.t002
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We used Prism4 (version 4.03, GraphPad Software, Inc.) for
data management, analysis and graphical presentation. We used
unpaired T tests to compare differences between groups, and
paired T tests to evaluate differences between study days within
groups.
Results
Automated production of S. Typhi proteins
We estimated that we required at least 20 mg of a specific
protein for use in our planned immunological assays. Our six
production runs resulted in the production of 20 mgo rm o r ef o r
25 of our selected 58 proteins; nine of these samples had purity by
LC90 Caliper analysis of .90%, and 17 had purity greater than
.80%. Purity was defined as the quantity of protein matching
the molecular size of the desired product. The LPS contamina-
tion of all preparations was found to be less than the level of
detection of our assay kit (,300 fg/ml). Of these 17 proteins with
sufficient quantity and purity, we selected 7 proteins for our initial
analysis (Table 1) representing a range of cellular location and
function, including a number involved in fimbrial attachment or
adhesion such as StaF (putative fimbrial protein encoded by
STY0202), StbB (fimbrial chaperone encoded by STY0372),
CsgF (involved in curli production encoded by STY1177), and
CsgD (a putative regulatory protein encoded by STY1179), as
well as OppA (a periplasmic oligopeptide binding protein
precursor involved in peptide transport encoded by STY1304),
a conserved hypothetical protein encoded by STY2195, and
PagC, an outer membrane protein encoded by STY1878 whose
expression is regulated by the PhoP regulon involved in intra-
macrophage survival [19,28].
Table 3. Proteins represented in the S. Typhi membrane preparations and selected S. Typhi antigens.
Accession Entry name Protein name Peptide Hits Rank*
Most abundant proteins
P0A1H6 EFTU_SALTI Elongation factor Tu (EF-Tu) 380 1
Q8Z7S0 OMPA_SALTI Outer membrane protein A (OmpA) 342 2
Q8Z8C8 Q8Z8C8_SALTI Succinate dehydrogenase flavoprotein subunit 298 3
Q8Z1T9 LAMB_SALTI Maltoporin (maltose-inducible porin) 250 4
Q8XGX4 ATPB_SALTI ATP synthase subunit beta 201 5
Q8XG95 ATPA_SALTI ATP synthase subunit alpha 185 6
P0A264 OMPC_SALTI Outer membrane protein C (porin ompC) 170 7
Q8Z9F0 Q8Z9F0_SALTI Pyruvate dehydrogenase E1 component 135 8
Q8Z4L6 PUR4_SALTI Phosphoribosylformylglycinamidine synthase 132 9
P0AA29 THIO_SALTI Thioredoxin-1 (Trx-1) 125 10
Q8Z9E6 Q8Z9E6_SALTI Aconitate hydratase 2 117 11
Q8Z937 FADE_SALTI Acyl-coenzyme A dehydrogenase 116 12
P0A1D4 CH60_SALTI 60 kDa chaperonin pProtein Cpn60) (GroEL protein) 105 13
Q8Z9A3 YAET_SALTI Outer membrane protein assembly factor yaeT 102 14
Q8XH17 Q8XH17_SALTI Outer membrane protein x 98 15
Q8Z858 Q8Z858_SALTI D-alanyl-D-alanine carboxypeptidase (penicillin-binding protein 6) 91 16
Q8Z6J0 Q8Z6J0_SALTI Phosphoenolpyruvate synthase 88 17
Q8XFH6 Q8XFH6_SALTI Peptidoglycan-associated lipoprotein 86 18
Q8Z8C6 Q8Z8C6_SALTI 2-oxoglutarate dehydrogenase E1 component 78 19
Q8Z7D2 Q8Z7D2_SALTI Aconitate hydratase 1 (Aconitate hydratase 1 (citrate hydro-lyase 1)) 75 20
Selected virulence proteins
Q8Z7H3 PHOQ_SALTI Virulence sensor histidine kinase (PhoQ) 70 29
Q8Z8L8 Q8Z8L8_SALTI Ferrienterobactin receptor (FepA) 38 103
Q8Z7H2 PHOP_SALTI Virulence transcriptional regulatory protein (PhoP) 37 104
Q8Z1P4 Q8Z1P4_SALTI Two-component response regulator (PmrA) 4 487
P61091 SLYA_SALTI Transcriptional regulator (SlyA) 4 543
Q8Z6B2 Q8Z6B2_SALTI Outer membrane invasion protein (PagC) 4 544
Q8Z3Y7 Q8Z3Y7_SALTI Putative uncharacterized protein associated with virulence (STY3182) 2 749
Q8Z727 HLYE_SALTI Hemolysin E (Cytotoxin ClyA) 1 859
S. Typhi proteins individually purified and also detected in S. Typhi membrane preparation
Q8Z7F0 Q8Z7F0_SALTI Periplasmic oligopeptide-binding protein (OppA) 15 225
Q8Z6B2 Q8Z6B2_SALTI Outer membrane invasion protein (PagC) 4 544
*Rank order of abundance.
doi:10.1371/journal.pntd.0001193.t003
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preparation
Our mass spectrometric analysis of S. Typhi membrane
preparation identified 934 S. Typhi proteins (636 with three or
more spectral counts), including many involved in energy
metabolism, protein synthesis and fate, cell envelope or peptido-
glycan synthesis or maintenance, cellular processes, proteins
involved in transport, proteins involved in regulatory functions,
and proteins involved in virulence and pathogenesis (Table 2 and
3 and Table S1). We also identified two of our 7 selected proteins
(OppA and PagC) in the S. Typhi membrane preparation.
Interferon-c ELISPOT responses and T cell
characterization
We found that patients with S. Typhi bacteremia had elevated
interferon-c ELISPOT responses at both acute and convalescent
stages of infection compared to healthy controls for all seven of the
purified S. Typhi proteins, as well as against S. Typhi crude
membrane preparation (P,0.05) (Figure 1). In contrast, responses
to PHA did not differ significantly between patients and healthy
controls, and minimal responses were detected against control
protein and KLH in both patients and healthy controls. To assess
whether interferon-c responses were CD4 or CD8-derived, we
used intracellular cytokine staining following stimulation with a
subset of proteins, and found that the majority of interferon-c
expressing cells were CD4-positive, although a CD8 positive
response was also detected (Figure 2).
Proliferation responses
To further evaluate responses, we selected the three proteins
associated with the highest interferon-c expression levels in
convalescent phase samples, as well as membrane preparation, for
inclusion in cellular proliferation assays. In comparison to healthy
Bangladeshi controls residing within the same S.T y p h ie n d e m ica re a ,
individuals with documented S. Typhi bacteremia had significantly
elevated proliferation indices at the acute stage of illness to StaF and
PagC (P,0.0120.0008), but not to STY2195, or crude membrane
preparation, and these acute stage responses further significantly
increased within bacteremic individuals by the convalescent period
compared to the acute stage responses (P#0.0220.001) (Figure 3).
We also detected a significantly increased proliferation response to
STY2195 and S. Typhi membrane preparation in bacteremic
patients at convalescence compared to acute phase samples and
compared to control patients (p#0.01).
Discussion
Cellular immune responses, including CD4 and CD8-mediated
interferon-c responses, play a critical role in clearing and
Figure 1. Interferon-c ELISPOT responses to S. Typhi antigens including StaF (STY0202), CsgF (STY1177), PagC (STY1878), StbB
(STY0372), CsgD (STY1179), OppA (STY1304), conserved hypothetical protein encoded by STY2195, S. Typhi membrane
preparation (MP), control protein, and phytohaemagglutinin (PHA) and keyhole limpet hemocyanin (KLH) during acute and
convalescent stage illness in S. Typhi bacteremic patients and in healthy controls (HC). Mean and standard error of the mean represented.
doi:10.1371/journal.pntd.0001193.g001
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there has been limited evaluation of cellular responses in humans
to wild-type S. Typhi. No animal model fully replicates host-
pathogen interactions and immunologic events that occur during
this human-restricted infection. Evaluation in humans has largely
focused on characterizing responses in recipients of attenuated
vaccine strains of S. Typhi [23,38,41,42,43,44]. We report here a
screening approach that permitted us to evaluate interferon-c and
proliferation responses to a number of bacterial antigens in S.
Typhi-infected humans in Bangladesh. We selected proteins that
we had previously identified in immuno-affinity screening assays
for humoral responses [28], and we recovered these selected
proteins using an automated system and high throughput
genomic and proteomic technologies. Although we were able to
generate adequate samples for only approximately a third of our
selected proteins for evaluation in humans, we feel that high
throughput approaches such as the one we describe will assist in
accelerating analysis of pathogens that express thousands of
antigens. For instance, S. Typhi contains approximately 4,400
open reading frames, and although protein microarrays can be
used to screen for humoral responses across the immunopro-
teome, no comparable system has yet been developed to assess
cellular immune responses in a high throughput manner, despite
the critical role that cellular immune responses play against
intracellular pathogens.
We recognize that high throughput purification techniques may
be compromised by issues of contamination, including with LPS
when expression occurs in E. coli vectors. However, LPS
contamination of all preparations was found to be less than the
level of detection of our assay kit (,300 fg/ml), we did not detect
cellular immune responses to control protein expressed and
purified from E. coli in the same manner as our S. Typhi proteins,
and we detected cellular immune responses in patients but not
healthy controls to purified S. Typhi proteins. All of these
observations suggest that the responses we observed were antigen-
specific and not due to contaminating LPS.
In the S. Typhimurium mouse model, CD4 and CD8 cells are
critical to the development of protective immunity, and control of
Salmonella infection involves prominent expression of interferon-c
by both CD4 and CD8 cells [24,25,26]. Overall, only a relatively
few defined class I and class II epitopes have been identified in the
S. Typhimurium mouse model, including epitopes in FliC and
SipC for CD4 cells, and OmpC and GroEL for CD8 cells
[24,40,45,46,47,48]. A number of Salmonella antigens are also able
to induce partially protective immunity when included in subunit-
based vaccines in mice, including flagellin, MIG-14 and SseB
(Salmonella antigens expressed in vivo), suggesting that immune
responses against a number of Salmonella antigens could contribute
to protective immunity [49,50,51].
In comparison to the murine data, evaluation of cellular
responses to S. Typhi in humans have largely involved individuals
who have received attenuated S. Typhi vaccine strains such as
Ty21a and CVD908 [23,38,41,42,43,44]. In concordance with
the mouse data, these studies have shown induction of interferon-
c-expressing CD4 and CD8 responses following vaccination
[23,24,38,42,52]. Interestingly, CD8 responses may involve both
Figure 2. Characterization of interferon-c CD4 and CD8 responses to S. Typhi antigens including StaF (STY0202), PagC (STY1878),
S. Typhi membrane preparation (MP), and PMA and keyhole limpet hemocyanin (KLH) during acute and convalescent stage illness
in S. Typhi bacteremic patients. Mean and standard error of the mean represented.
doi:10.1371/journal.pntd.0001193.g002
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F, and G) mediated T cell recognition [43,52]. Using an ex vivo
model, Sztein and colleagues have also recently found that direct
infection of antigen-presenting dendritic cells with S. Typhi leads
to expression of high levels of TNF-a, IL-6 and IL-8, and low
levels of interferon-c and IL-12 p70, but that dendritic cells can
also ingest other infected human cells leading to high level
expression of interferon-c and IL-12 p70, with subsequent
induction of a population of CD3+CD8+CD45RA-CD62L-
effector/memory T cells in co-cultured lymphocytes [53]. Based
on these observations, we used recombinant antigens to assess
and characterize interferon-c and proliferation responses in
infected humans in Bangladesh. To establish the feasibility of
our approach, we focused our initial efforts on a subset of proteins
that we had previously identified as generating humoral
immunity and being expressed in vivo during human infection
[28]. These included a number involved in fimbrial attachment
or adhesion such as StaF, StbB, CsgF, and CsgD, as well as
OppA, a conserved hypothetical protein encoded by STY2195,
and PagC, an outer membrane protein encoded by STY1878.
We previously found that humans infected with S. Typhi develop
a serum antibody response to PagC and that this response
increases at convalescence [28]. Here we furthered this
observation and report detection of a parallel cellular response
against PagC during human infection, including both interferon-
c and proliferative responses, and show that responses in
convalescence were higher than during acute stage illness.
Although the role of PagC during human infection is not fully
understood, its expression is controlled by the PhoP-regulon
involved in intra-macrophage survival [19,54].
We also detected significant increases in cellular responses
during convalescence against StaF, a fimbrial protein homologous
to E. coli YadK that contains a Pfam motif believed to be involved
in cellular adhesion [17], STY2195, a conserved hypothetical
protein of unknown function, and a crude membrane preparation
containing over 900 S. Typhi proteins, including GroEL, OmpC,
OppA and PagC.
We found that S. Typhi proteins elicit both CD4
+ and CD8
+
interferon-c expressing responses, with CD4 responses being
more numerous than CD8 responses. Of interest, we were able to
detect antigen-specific interferon-c responses in patients, includ-
ing at the time that patients presented for clinical care, but similar
responses were not seen on controls. These observations suggest
that an antigen-specific interferon-c-based detection system might
be used to diagnose individuals with typhoid fever during the
acute stage of illness, similar to the approach used to diagnose
infection with Mycobacterium tuberculosis [55,56,57]. Currently, all
available diagnostic tests for typhoid fever lack either sensitivity
and/or specificity, especially in areas of the world endemic for
typhoid. For example, microbiological culturing of blood has
approximately 30–70% sensitivity, depending on the volume of
blood obtained and whether previous antibiotics have been
administered, and the Widal assay has at best 85% specificity
when analyzing both acute and convalescent phase responses in
Figure 3. Cellular proliferation responses to S. Typhi antigens including StaF (STY0202), PagC (STY1878), conserved hypothetical
protein encoded by STY2195, S. Typhi membrane preparation (MP), control protein, and phytohaemagglutinin (PHA) and keyhole
limpet hemocyanin (KLH) during acute and convalescent stage illness in S. Typhi bacteremic patients and in healthy controls (HC).
Stimulation index: net cpm with antigen /net cpm without antigen (media alone) for each individual on each day (acute and convalescent). Mean and
standard error of the mean represented.
doi:10.1371/journal.pntd.0001193.g003
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59,60].
In summary, we have used a screening format to preliminarily
characterize S. Typhi antigen-specific interferon-c responses in
patients with typhoid fever. This is the first characterization of
such responses in humans, and further immunologic analysis will
be required to assess the role, if any, that these responses play in
controlling or clearing S. Typhi infection. Our study has a number
limitations, including analysis of a relatively small number of
purified S. Typhi antigens, characterization of a limited number of
immunologic parameters, and the absence of the inclusion of
febrile control patients confirmed not to be acutely infected with S.
Typhi; however, our detection of antigen-specific interferon-c
responses could assist in the development of interferon-c-based
diagnostic assays for typhoid fever, and our overall approach could
be used to identify antigens capable of inducing cellular immune
responses during infection with other intracellular pathogens.
Supporting Information
Table S1 Mass spectrometric analysis of S. Typhi
membrane preparation.
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